Pieris Q3 net loss $9.7M ($0.13/sh); cash at $69.8M, funded into Q2 2024

PALVELLA THERAPEUTICS, INC.

Net loss of $9.7M ($0.13 per share) vs $16.5M ($0.24) in Q3 2021.
Cash and investments $69.8M at Sept 30, down from $117.8M at Dec 31, 2021; company expects funding into Q2 2024.
R&D expense $13.6M (down from $18.9M); G&A $3.9M (down from $4.1M).
Elarekibep Phase 2a asthma study enrollment continues; topline FEV1 results expected by Q3 2023.
PRS-220 Phase 1 first subject dosed; IND accepted for SGN-BB228; PRS-342 Phase 1 start within 6 months.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PALVELLA THERAPEUTICS, INC. reported financial results for the third quarter of 2022 ended September 30, 2022.

Period: the third quarter of 2022 ended September 30, 2022
Result: reported results

Exact text from the filing

On November 2, 2022, Pieris Pharmaceuticals, Inc. (the “Company”) issued a press release announcing certain financial results for the quarter ended September 30, 2022.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

PALVELLA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-22-025458

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.